Patent ID: 7824865

Claim:
A method of evaluating the progression of acute myelocytic leukemia (AML) in a patient afflicted with AML to determine whether said patient is in remission, said method comprising: (a) obtaining a first sample of serum of the patient; (b) obtaining a second sample of serum of the patient later in time; (c) immunoreacting a WT1 antigen with any anti-WT1 antibody present in each of said first and second samples, wherein said anti-WT1 antibody can bind to an antigen consisting of amino acids 1-294 of SEQ ID NO:5; (d) comparing the amount of anti-WT1 antibody present in said first sample to the amount of anti-WT1 antibody present in said second sample; and (e) determining whether the amount of anti-WT1 antibody present in the second sample is less than the amount of anti-WT1 antibody present in the first sample, and is below the detection limit; wherein when the amount of anti-WT1 antibody present in the second sample is less than the amount of anti-WT1 antibody present in the first sample, and is below the detection limit, said patient is in complete remission.